Soliman, Sameh S. M. https://orcid.org/0000-0002-7691-615X
Baldin, Clara
Gu, Yiyou
Singh, Shakti https://orcid.org/0000-0001-6521-0998
Gebremariam, Teclegiorgis https://orcid.org/0000-0002-2295-058X
Swidergall, Marc https://orcid.org/0000-0002-5261-6267
Alqarihi, Abdullah https://orcid.org/0000-0003-4408-6398
Youssef, Eman G. https://orcid.org/0000-0002-3167-1347
Alkhazraji, Sondus
Pikoulas, Antonis
Perske, Christina
Venkataramani, Vivek
Rich, Abigail https://orcid.org/0000-0002-7301-1945
Bruno, Vincent M.
Hotopp, Julie Dunning https://orcid.org/0000-0003-3862-986X
Mantis, Nicolas J. https://orcid.org/0000-0002-5083-8640
Edwards, John E. Jr
Filler, Scott G. https://orcid.org/0000-0001-7278-3700
Chamilos, Georgios
Vitetta, Ellen S.
Ibrahim, Ashraf S. https://orcid.org/0000-0003-3787-8530
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R00DE026856)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01A11752861)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI063503)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI141360)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U19AI110820)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI141360)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI124566)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01DE022600)
Article History
Received: 27 January 2020
Accepted: 20 November 2020
First Online: 18 January 2021
Competing interests
: A.S.I. owns shares in Vitalex Biosciences, a start-up company that is developing immunotherapies and diagnostics for mucormycosis. The Lundquist Institute has filed intellectual property rights concerning mucoricin (US patent application no. 16/462,511). Vitalex Biosciences has an option to license the technology from The Lundquist Institute for Biomedical Innovation. The remaining authors declare no competing interests.